logo

Stocks to Watch Today, Wednesday, November 18, 2026: HCL Technologies, IIFL Finance, Ashoka Buildcon, Glenmark Pharma, Advait Energy Transitions 

Authored By HDFC SKY | Last Modified: Nov 18, 2026 09:23 AM IST

Stocks in News
ADVAIT
₹1,860
-0.16%
GLENMARK
₹2,635.50
-0.40%
ASHOKA
₹113.50
-1.48%
IIFL
₹647.25
-2.22%
HCLTECH
₹1,318.20
-1.97%
Stocks to Watch Today, Wednesday, November 18, 2026: HCL Technologies, IIFL Finance, Ashoka Buildcon, Glenmark Pharma, Advait Energy Transitions 

Open Free Demat Account

By signing up I certify terms, conditions & privacy policy

New Delhi, Nov 18: Here are five stocks in focus on Wednesday, from HCL Technologies’ partnership with Cohere for sovereign AI to Fairfax’s planned Rs 3,454 crore block deal in IIFL Finance to Ashoka Buildcon’s Rs 1,465 crore NHAI bid to Glenmark Pharma’s US FDA filing for ISB 2301 to target solid tumors and Rs 130.48 crore GETCO order for Advait Energy Transitions. Here’s what’s driving each stock and what to track through the session. 

HCL Technologies (HCLTECH) 

HCL Technologies has partnered with Canada-based Cohere to develop and deliver sovereign artificial intelligence (AI) solutions for enterprises and governments, initially focusing on Canada and Germany. The partnership will combine Cohere’s AI platform and models with HCLTech’s enterprise AI capabilities, targeting applications across insurance, financial services and manufacturing. 

Sovereign AI refers to AI systems that are built, hosted and run within a country’s own borders and rules, which matters to governments and regulated industries that cannot send sensitive data to foreign platforms. The initial focus on Canada and Germany points to two markets with strict data protection rules. The update does not mention any financial terms, so investors will track how quickly the partnership turns into client contracts. 

IIFL Finance (IIFL) 

Canada-based Fairfax Financial Holdings is planning to sell up to a 13.25 per cent stake in IIFL Finance through a block deal, involving up to 5.65 crore shares worth approximately Rs 3,454 crore. The floor price has been set at Rs 611 per share, nearly 4 per cent below the prevailing market price, according to sources cited by reports.

At the floor price, 5.65 crore shares work out to about Rs 3,452 crore, in line with the reported size of the deal, and the discount of nearly 4 per cent implies a market price of about Rs 636. Block deals are large trades done in a single transaction, and a sale priced below the market can weigh on a stock in early trade, so investors will track the final size, the buyers and the closing price. 

Ashoka Buildcon (ASHOKA) 

Ashoka Buildcon has emerged as the lowest bidder for a Rs 1,465 crore project awarded by the National Highways Authority of India (NHAI), excluding GST. The contract involves completing work on a 35.4-km stretch of the eight-lane Vadodara-Mumbai Expressway between Jujuwa and Gandeva in Gujarat. 

The bid works out to about Rs 41.4 crore per km of the stretch. Being the lowest bidder is not the same as winning the contract, as the award is subject to the authority’s final approval. The company has been in focus for orders on the same expressway, with a Rs 866 crore NHAI contract reported on November 10, and investors will track whether the lowest-bidder status is converted into a formal award. 

Glenmark Pharma (GLENMARK) 

Ichnos Glenmark Innovation Inc. (IGI), a global clinical-stage biotechnology company, has announced the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for ISB 2301. ISB 2301 is a first-in-class investigational multispecific immune cell activator designed to target three tumour-associated antigens and engage both T cells and natural killer (NK) cells. 

An IND application is the step that precedes human trials in the US, and the FDA has 30 days to review it before a study can begin unless it raises concerns. The filing is not an approval, and the molecule remains at an early stage of development. For Glenmark Pharma, the news is about its innovation pipeline and not near-term revenue, so investors will track the FDA’s response and the plans for a first clinical study. 

Advait Energy Transitions (ADVAIT) 

Advait Energy Transitions has received an order worth Rs 130.48 crore from Gujarat Energy Transmission Corporation (GETCO) for the supply, installation, testing and commissioning of the reconductoring of the 220 kV Dahej–Haldarwa Line-1 and 220 kV Dahej–Haldarwa Line-2 in the Bharuch Circle. The project involves replacing the existing ACSR Zebra conductors with higher-ampacity conductors. 

Reconductoring raises the power-carrying capacity of an existing line by changing its conductors, which avoids the land and right-of-way issues of building a new line. The order covers two parallel lines and adds to the transmission-related orders in focus this month, such as Power Grid’s Humnabad project reported on November 12. 

Sources

  • Company filings and media reports 
Disclaimer

The information shared here is intended solely for informational and educational purposes and does not constitute investment recommendations. While we practice strict due diligence in curating daily market data, readers must perform independent research before trading. To flag any real-time data discrepancies or content concerns, please write to us at content@hdfcsec.com.

Summarize with AI
Google GeminiChatGPTPerplexity AIAnthropic AIGrok AI
Desktop BannerMobile Banner

Invest Anytime, Anywhere

Get it on Google PlayGet it on App Store

Open Free Demat Account Online

By signing up I certify terms, conditions & privacy policy